Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is… Read more
Dimerix Ltd (SBMJF) - Net Assets
Latest net assets as of June 2025: $13.38 Million USD
Based on the latest financial reports, Dimerix Ltd (SBMJF) has net assets worth $13.38 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($91.18 Million) and total liabilities ($77.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $13.38 Million |
| % of Total Assets | 14.67% |
| Annual Growth Rate | 73.74% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 378.58 |
Dimerix Ltd - Net Assets Trend (2021–2025)
This chart illustrates how Dimerix Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Dimerix Ltd (2021–2025)
The table below shows the annual net assets of Dimerix Ltd from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $13.38 Million | -26.43% |
| 2024-06-30 | $18.19 Million | +204.97% |
| 2023-06-30 | $5.96 Million | -58.65% |
| 2022-06-30 | $14.42 Million | +882.13% |
| 2021-06-30 | $1.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dimerix Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5462020300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $95.81 Million | 716.08% |
| Total Equity | $13.38 Million | 100.00% |
Dimerix Ltd Competitors by Market Cap
The table below lists competitors of Dimerix Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hoteles City Express S.A.B. de C.V
PINK:HOCXF
|
$117.76 Million |
|
IGPTF
PINK:IGPTF
|
$117.76 Million |
|
Spero Therapeutics Inc
NASDAQ:SPRO
|
$117.83 Million |
|
Grupo Minsa S.A.B. de C.V
MX:MINSAB
|
$117.84 Million |
|
CHT Security Co., Ltd.
TW:7765
|
$117.63 Million |
|
Izmir Demir Celik Sanayi AS
IS:IZMDC
|
$117.61 Million |
|
Douglas Elliman Inc
NYSE:DOUG
|
$117.59 Million |
|
Sukgyung AT Co. Ltd.
KQ:357550
|
$117.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dimerix Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 18,185,510 to 13,379,343, a change of -4,806,167 (-26.4%).
- Net loss of 13,251,722 reduced equity.
- New share issuances of 7,546,795 increased equity.
- Other factors increased equity by 898,760.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.25 Million | -99.05% |
| Share Issuances | $7.55 Million | +56.41% |
| Other Changes | $898.76K | +6.72% |
| Total Change | $- | -26.43% |
Book Value vs Market Value Analysis
This analysis compares Dimerix Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.18x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 34.31x to 11.18x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | $0.01 | $0.25 | x |
| 2022-06-30 | $0.04 | $0.25 | x |
| 2023-06-30 | $0.02 | $0.25 | x |
| 2024-06-30 | $0.03 | $0.25 | x |
| 2025-06-30 | $0.02 | $0.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dimerix Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -99.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -237.20%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 6.81x
- Recent ROE (-99.05%) is above the historical average (-186.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -433.89% | 0.00% | 0.00x | 6.42x | $-6.52 Million |
| 2022 | -72.74% | 0.00% | 0.00x | 1.14x | $-11.93 Million |
| 2023 | -231.47% | 0.00% | 0.00x | 2.98x | $-14.40 Million |
| 2024 | -93.89% | -4190.55% | 0.01x | 1.76x | $-18.89 Million |
| 2025 | -99.05% | -237.20% | 0.06x | 6.81x | $-14.59 Million |
Industry Comparison
This section compares Dimerix Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dimerix Ltd (SBMJF) | $13.38 Million | -433.89% | 5.81x | $117.63 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |